RE: Annual budget16 Mar 2023 12:47
Poolbeg also partnered with AI-led company OneThree Biotech in February of 2022 to identify new drug targets and treatments for Respiratory Syncytial Virus. Working together, the collaboration aims to build a tailored AI analysis model, using human challenge trial data to identify disease-relevant cell signalling pathways which could lead to novel drug targets. In December 2022, Poolbeg announced that the collaboration had identified a number of promising drug candidates. Again, Poolbeg notes that the analysis will prioritise drugs with existing Phase I safety data, majorly reducing time and costs.
Both partnerships are industry firsts, with the OneThree Biotech partnership marking the first time AI analysis has been undertaken on RSV human challenge trial data and equally, the collaboration with CytoReason marking the first time AI has been used to analyse influenza human challenge trial data. In this sense, Poolbeg is yards beyond its competitors and demonstrates how AI can be incredibly beneficial in speeding up the otherwise timely and costly drug discovery process.